GHP December

18 | ghp December 2016 Innovation & Technology A Promising Foundation nly one of a handful of corporations in Québec and in Canada to have discovered, developed and commercialized its own product, Theratechnologies has now moved from being a purely biotech company to a specialty pharmaceutical company, with its own initial product. The company has also recently acquired the commercial rights for a second product to be launched in 2017, pending approval. With these developments in the pipeline, Luc Tanguay expresses his intention of remaining focused on catering to the needs of people living with HIV. “I have been active in the biotechnology industry for over 20 years,” Luc begins. “I have been a member of the board of directors of Theratechnologies since 1993, CFO from 1996 to 2012, and I became CEO at the end of 2012. As a member of the Corporation’s senior management since 1996, I have contributed to the Corporation’s growth by facilitating access to public and private capital funding, and since 2012 by transforming the company into a more commercial oriented organization. Prior to joining the Corporation, I had a career in investment banking in healthcare at National Bank Financial Inc.” Owing chiefly to its privileged position in the Canadian biotech and pharmaceutical industries, Theratechnologies has been enjoying promising growth in recent years. In 2015, for instance, its stock value quadrupled; in 2016 this figure doubled in value again. In both years, the company has significantly outperformed the index, a feat that Luc puts down to the employees. “Our employees play a very important role at Theratechnologies,” Luc says. “Like many other biotech companies, we went through some very difficult times, but now, our employees, by their resilience, their talent and their loyalty have shaped the organization into what it is today.” Today, the major test facing Theratechnologies is to manage its growth correctly. With its initial product growing nicely on the market, and the new one expected to become a game changer, Luc revels in the challenge ahead of applying the proper balance in managing the resources and capturing the potential of those opportunities. Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients. Its President and CEO, Luc Tanguay, M.Sc., CFA, is also recognised by GHP as the President of the Year, Canada. Theratechnologies Inc. www.theratech.com 2015 Peel Street, 5th Floor, Montreal, Québec H3A 1T8, Canada O Luc Tanguay President & CEO of Theratechnologies Inc. gies